Equillium Results Presentation Deck

Exploratory Analysis of SLE Subjects with Elevated Proteinuria Low grade proteinuria is both present and treatable in patients with SLE and provides positive signal of drug activity for the treatment of lupus nephritis Fold Change in UPCR or ACR Itolizumab mean fold change in elevated proteinuria in SLE patients¹ (baseline UPCR > 0.2 g/g, n=6; or ACR> 0.03 g/g, n=4) 1.0 Os equillium Baseline Day 29 Day 57 N 6 6 5 Spot UPCR Change from Mean (n/a) 0.49 Baseline (3) NA į Dosing days I +42 N 4 2 4 ACR Change from Meon (g/n) Baseline (25) 0.39 0.17 Study Day Fold Change in Unne Protein Create Rato -54 43 Fold Change in Urine AlbumCreate a 4 Median % Change Belimumab median % reduction in elevated proteinuria in SLE patients² (baseline UPCR > 0.2 g/g) -Belimumab 1 mg/kg, n=202 Belimumab 10 mg/kg, n=228 0 -10 -20 -30 -40 -50 Placebo, n=215 0 N=6 4 N=5 Itolizumab 8 12 # 16 20 24 28 32 36 40 44 48 52 Weeks Belimumab median reduction in UPCR of 38% at week 52² Itolizumab median reduction in UPCR of 43% at week 8¹ Abbreviations: ACR urine albumin-to-creatinine ratio, UPCR urine protein-to-creatinine ratio, SE standard error, Interim data from 30 July 2021. Change from baseline = (geometric mean of subject specific fold changes from baseline -1) x 100, Data are not available for all subjects at all timepoints. 1. Putterman et al., PO1624 ASN., 2021; 2. Dooley et al., Lupus, 2013, itolizumab data represented for illustrative purposes 18

View entire presentation